Automated Patch-clamp
Automated patch clamp is an important part of our services for institutes and drug discovery companies. Creative Bioarray has a group of experienced scientists with decades of electrophysiological work experience. High-throughput detection can be achieved on the premise of accurate measurement, and 16 cells can be simultaneously detected each time. Our automated planar patch-clamp method on genetically modified mammalian cell lines for voltage- and ligand-gated ion channels as well as temperature-activated channels can be reached in gigaseal quality.
Besides providing a better support in drug discovery (ion channel screening), Creative Bioarray meets higher throughput demands of early hERG risk assessment. We performed hERG safety evaluation in a GLP-compliant standard process with indicators qualified for new drug declaration. Over hundreds of compounds have been tested in our automated patch-clamp system.
Systems
The Qube 384 and QPatch 16 of Sophion's high throughput screening system covers a wide range of throughput needs and provide the user with genuine whole-cell patch clamp data based on true gigaseals. Both can be used on almost any ion channel target. These are fully automated patch-clamp platforms that allow for the testing of up to 48 and 16 cells in parallel, respectively. These become our ways of making ion channel research easy, confirming hits from larger screens and also for lead optimization.
The QPatch machines offer high quality measurements with the formation of gigaohm seals. The platform can be used to assay both voltage-gated and ligand-gated channels and utilizes stable cell lines.
Advantages
Meeting the higher throughput demands of ion channel screening and early hERG risk assessment
Combined with our long-standing expertise in ion channel research and automation of electrophysiological assays, we offer high quality ion channel screening together with a careful data analysis and thorough data interpretation
Screening on other voltage-gated and ligand-gated targets
Positive control and vehicle control in every assay
Single concentration profiling and full concentration response curves
Applications
- hERG screening service:
Proven benchmark platform for cardiac safety.
Compound profiling against hERG to evaluate potential cardiac liability.
Detect hERG-related safety issues at early stages in the drug development process. - Screening on other voltage-gated and ligand-gated targets
Both Current clamp and voltage clamp available.
QPatch outsourcing service
If you have established QPatch assays but limited instrumental capacity our outsourcing service will help you balance the load.
Fig. 1 Inhibition of hNaV and hCaV3 subtypes by μ‐TRTX‐Df1a measured by automated patch clamp electrophysiology in QPatch 16X
In Creative Bioarray, Qube is another automated patch-clamp system of high-throughput ion channel screening and characterization, intended for use in laboratories with a need for up to thousands of data points per day. Qube finally bridges the gap between high throughput and high fidelity in ion channel assays and provides:
90-95% success rates easily achieved
True walkaway operation – 6,000 wells tested with a single click
All ion channel questions answered with voltage, ligand and current clamp recordings
Gigaseal recording ensure high fidelity data and high signal to noise ratio
Temperature control
Intelligent compound handling to ensure correct concentrations at measurement site
Enables staff rotation with easy to use assay setup interface
Powerful analysis with Sophion Analyzer Software
Rely on our long-standing expertise in ion channel research and automation of ion channel assays. Creative Bioarray offers assays to study drug effects on voltage-gated and ligand-gated ion channels as well as customer-tailored solutions and assay development. Please contact us for specific targets and assay development according to your needs.
Reference
Cardoso FC, et al. Modulatory features of the novel spider toxin μ-TRTX-Df1a isolated from the venom of the spider Davus fasciatus. Br J Pharmacol. 2017; 174: 2528–2544.
Inquiry
